ERBB2 and breast carcinoma: The advent of anti-estrogenic compounds such as tamoxifen in the treatment of hormone-receptor positive breast cancers [24] and the monoclonal antibody trastuzumab to treat HER2+ breast cancer [25] have demonstrated the utility in targeting breast cancer with therapies based on genomic, transcriptomic, and immunohistochemical data.